Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
A phase 2 trial of trastuzumab and serplulimab in gallbladder cancer and other biliary tract cancers, run by Xiujuan Qu, now recruiting.
Overview
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy is a phase 2 interventional study registered as NCT07506057 by Xiujuan Qu, with a registry enrolment figure of 20 participants, started 2025-07-15 and due to reach its primary completion in 2027-07. Interventions recorded: Trastuzumab+Serplulimab. Conditions listed: Urothelial Carcinoma, Biliary Tract Cancer, HER2. Sites: China. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSurufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
Shares Serplulimab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialTrastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Trastuzumab, Biliary tract cancer (all types), Monoclonal antibodies and the tag gallbladder-deep-dive.
- TrialAgnostic Therapy in Rare Solid Tumors
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.
- TrialEvaluating Novel Therapies in ctDNA Positive GI Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Monoclonal antibodies, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialChemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.
- TrialA Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.
- TrialA Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.
- TrialCombined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Monoclonal antibodies, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.